114 related articles for article (PubMed ID: 37291789)
1. Designing and
Patil SM; Shashikant B
Curr Drug Discov Technol; 2023; 20(6):47-59. PubMed ID: 37291789
[TBL] [Abstract][Full Text] [Related]
2. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
3. In Search of HIV Entry Inhibitors Using Molecular Docking, ADME, and Toxicity Studies of Some Thiazolidinone-Pyrazine Derivatives Against CXCR4 Co-receptor.
Patil SM; Asgaonkar KD; Bakhle B; Abhang K; Khater A; Singh M; Chitre TS
Curr HIV Res; 2022 Aug; 20(2):152-162. PubMed ID: 35156573
[TBL] [Abstract][Full Text] [Related]
4. Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer.
Kumar S; Sengupta S; Ali I; Gupta MK; Lalhlenmawia H; Azizov S; Kumar D
J Biomol Struct Dyn; 2023; 41(21):11353-11372. PubMed ID: 37114510
[TBL] [Abstract][Full Text] [Related]
5. A Review: Discovering 1,3,4-oxadiazole and Chalcone Nucleus for Cytotoxicity / EGFR Inhibitory Anticancer Activity.
Patil S; Bhandari S
Mini Rev Med Chem; 2022; 22(5):805-820. PubMed ID: 34477516
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
[TBL] [Abstract][Full Text] [Related]
7. Design, In Silico Molecular Docking, and ADMET Prediction of Amide Derivatives of Chalcone Nucleus as EGFR Inhibitors for the Treatment of Cancer.
Patil SM; Randive V; Mahadik I; Asgaonkar K
Curr Drug Discov Technol; 2023 Nov; ():. PubMed ID: 37921215
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
9. Biological Evaluation and Molecular Dynamics Simulation of Chalcone Derivatives as Epidermal Growth Factor-Tyrosine Kinase Inhibitors.
Sangpheak K; Tabtimmai L; Seetaha S; Rungnim C; Chavasiri W; Wolschann P; Choowongkomon K; Rungrotmongkol T
Molecules; 2019 Mar; 24(6):. PubMed ID: 30897725
[TBL] [Abstract][Full Text] [Related]
10. Hydrazide-hydrazones as Small Molecule Tropomyosin Receptor Kina se A (TRKA) Inhibitors: Synthesis, Anticancer Activities,
Alam MS; Lee DU
Med Chem; 2022; 19(1):47-63. PubMed ID: 35490310
[TBL] [Abstract][Full Text] [Related]
11. In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies.
Kumar S; Ali I; Abbas F; Khan N; Gupta MK; Garg M; Kumar S; Kumar D
In Silico Pharmacol; 2023; 11(1):20. PubMed ID: 37575679
[TBL] [Abstract][Full Text] [Related]
12. In silico screening of chalcone derivatives as promising EGFR-TK inhibitors for the clinical treatment of cancer.
Mathpal S; Joshi T; Sharma P; Maiti P; Nand M; Pande V; Chandra S
3 Biotech; 2024 Jan; 14(1):18. PubMed ID: 38130684
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of anti-EGFR potential of quinazoline derivatives using molecular docking: An in silico approach.
Tanveer F; Anwar MF; Siraj B; Zarina S
Biotechnol Appl Biochem; 2022 Jun; 69(3):1226-1237. PubMed ID: 34028091
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
Alswah M; Bayoumi AH; Elgamal K; Elmorsy A; Ihmaid S; Ahmed HEA
Molecules; 2017 Dec; 23(1):. PubMed ID: 29280968
[TBL] [Abstract][Full Text] [Related]
15. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
16.
Kumar S; Ali I; Abbas F; Rana A; Pandey S; Garg M; Kumar D
J Biomol Struct Dyn; 2023 Aug; ():1-23. PubMed ID: 37646177
[TBL] [Abstract][Full Text] [Related]
17. Molecular interaction study of novel indoline derivatives with EGFR-kinase domain using multiple computational analysis.
Palanivel S; Yli-Harja O; Kandhavelu M
J Biomol Struct Dyn; 2022 Oct; 40(16):7545-7554. PubMed ID: 33749517
[TBL] [Abstract][Full Text] [Related]
18. An
Malkaje S; Srinivasa MG; Deshpande N S; Navada S; Revanasiddappa Bc
Curr Drug Res Rev; 2023; 15(1):88-100. PubMed ID: 36017854
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
20. Structure-based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Metabolic Reactivity Studies of Quinazoline Derivatives for their Anti-EGFR Activity Against Tumor Angiogenesis.
Shah AA; Ahmad S; Yadav MK; Raza K; Kamal MA; Akhtar S
Curr Med Chem; 2024; 31(5):595-619. PubMed ID: 36892124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
